Study design and participants
infection, heart failure, Cancer
HEART, INFECTION, ONCOLOGY, HEART FAILURE, CANCER
Patients with R-R Philadelphia chromosome-negative CD22-positive pre-B ALL were eligible. Patients had to have an Eastern Cooperative Oncology Group (ECOG) performance status of 3 or better, normal cardiac function (defined by an ejection fraction above 50%), and adequate organ functions (serum bilirubin ≤ 1.95 mg/dL and serum creatinine ≤ 2.0 mg/dL). Patients were excluded if they had an active infection not controlled by antibiotics, clinical evidence of grade 3 to 4 heart failure as defined by the New York Heart Association criteria, or second active malignancy. All patients signed a consent form in accordance with the Declaration of Helsinki. This study was approved by the Institutional Review Board of The University of Texas MD Anderson Cancer Center. The trial was registered on clinicaltrials.gov with the identifier NCT01371630.